Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Clover Launches COVID-19 Vaccine in China as Second Booster Dose

publication date: Feb 14, 2023

Clover Biopharma launched its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in China as a second booster dose (fourth vaccination dose) for older adults, immunocompromised individuals and individuals with comorbidities. The launch will start in Zhejiang province and move to additional areas in Q1 2023. In a global trial that enrolled over 30,000 participants, Clover’s vaccine showed a fivefold increase in neutralizing antibodies against the BA.5 omicron compared to a third dose of an inactivated vaccine. The vaccine was approved on an emergency use basis in China two months ago. More details....

Stock Symbol: (HK: 02197)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital